JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Kodu・Aktsiate loetelu・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

38.99 -0.1

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

38.75

Max

39.11

Põhinäitajad
By Trading Economics
Sissetulek	7.3M -123M
Müük	3.7M 3.9M
Aktsiakasum	-1.29
Kasumimarginaal	-3,161.261
Töötajad	594
EBITDA	20M -122M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+109.53% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-445M 4B
Eelmine avamishind	39.09
Eelmine sulgemishind	38.99

Uudiste sentiment

By Acuity

50%

116 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

30.39 / 33.46 Toetus ja vastupanu

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. mai 2026, 23:43 UTC

Uudisväärsed sündmused

New Zealand's Unemployment Rate Falls in 1Q

5. mai 2026, 23:20 UTC

Kuumad aktsiad

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5. mai 2026, 21:48 UTC

Tulu

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5. mai 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6. mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5. mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5. mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5. mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5. mai 2026, 22:08 UTC

Tulu

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5. mai 2026, 22:07 UTC

Tulu

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Rev $1.2B >PAAS

5. mai 2026, 21:42 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:38 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:30 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:29 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:26 UTC

Tulu

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q EPS 39c >ALC.EB

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5. mai 2026, 21:24 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:18 UTC

Tulu

Mistras Backs 2026 Rev $730M-$750M >MG

5. mai 2026, 21:17 UTC

Tulu

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5. mai 2026, 21:15 UTC

Tulu

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5. mai 2026, 21:12 UTC

Tulu

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5. mai 2026, 21:11 UTC

Tulu

SSR Mining 1Q Rev $581.8M >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q Adj EPS $1.15 >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q EPS $1.16 >SSRM

5. mai 2026, 21:08 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:01 UTC

Tulu

Intact Financial 1Q EPS C$4.12 >IFC.T

5. mai 2026, 21:01 UTC

Kuumad aktsiad

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

109.53% tõus

12 kuu keskmine prognoos

Keskmine 86.43 USD 109.53%

Kõrge 97 USD

Madal 67 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Crinetics Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

30.39 / 33.46Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

116 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.